Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 5/20 | 0.59 |
| ▸ | PIM1 | P11309 | 3/20 | 0.59 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.47 |
| ▸ | NFATC1 | O95644 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 3/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067091 | 1.00 | HASPIN (0.59) | HASPINPIM1HTR6DYRK1ANFATC1 | |
| SCHEMBL245511 | 0.83 | DYRK1A (0.61) | HASPINPIM1HTR6DYRK1ANFATC1 | |
| SCHEMBL14059758 | 0.75 | GSK3B (0.51) | HASPINPIM1HTR6DYRK1ANFATC1 | |
| SCHEMBL10587 | 0.75 | PIM1 (0.59) | HASPINPIM1HTR6DYRK1ANFATC1 | |
| SCHEMBL30295197 | 0.75 | PIM1 (0.59) | HASPINPIM1HTR6DYRK1ANFATC1 | |
| SCHEMBL3224448 | 0.75 | ATM (0.52) | HASPINPIM1HTR6DYRK1ANFATC1 | |
| SCHEMBL16168495 | 0.75 | HTR6 (0.56) | HASPINPIM1HTR6DYRK1ANFATC1 | |
| SCHEMBL29535106 | 0.75 | ATM (0.52) | HASPINPIM1HTR6DYRK1ANFATC1 | |
| SCHEMBL245955 | 0.75 | KDM4C (0.47) | HASPINPIM1HTR6DYRK1ANFATC1 | |
| SCHEMBL245345 | 0.75 | KDM4C (0.47) | HASPINPIM1DYRK1ANFATC1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20240398812-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4440703-A1 | HETEROCYCLIC COMPOUNDS AS GCN2 AND PERK KINASE INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4408849-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4408850-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118317963-A | TRPML modulators, compositions thereof, and methods of use | 卡拉韦治疗公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| WO-2015044267-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2014053968-A1 | PYRROLO[3,2-C]PYRIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-04-10 | — | — | WO | disclosed |
| EP-2519520-A1 | [4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLOPYRIDINYL)-METHANONE DERIVATIVES AS TRYPTASE INHIBITORS | SANOFI (FR) | 2012-11-07 | — | — | EP | disclosed |
| CN-102770431-A | [4[4- (5-aminomethyl-2-fluoro-phenyl) -piperidin-1-yl ] - (1H-pyrrolopyridin-yl) -methanone and its synthesis | SANOFI SA | 2012-11-07 | — | — | CN | disclosed |
| US-20120245199-A1 | [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245199-A1 | [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245199-A1 | [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011078984-A1 | [4[4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011078984-A1 | [4[4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011038579-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZHEJIANG BETA PHARMA INC. (CN) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | HASPIN 1445/4885PIM1 1233/4885HTR6 2495/4885 |
| US-20240398812-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | MCOLN1, PKD2, MCOLN3 | HASPIN 1587/4885PIM1 4693/4885HTR6 1165/4885 |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | MCOLN1, TRPM2, PKD2 | HASPIN 1525/4885PIM1 4683/4885HTR6 1165/4885 |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | HASPIN 890/4885PIM1 942/4885HTR6 3717/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | HASPIN 387/4885PIM1 1476/4885HTR6 4242/4885 |
| US-20120245199-A1 | [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | CMA1, TPSB2, TPH1 | HASPIN 2268/4885PIM1 2687/4885HTR6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.